The price of GLP-1 drugs has attracted the scrutiny of lawmakers, and Novo Nordisk's chief executive Lars Fruergaard Jrgensen has agreed to appear at a Senate hearing next week to defend the pricing of the group's semaglutide-based therapies
The rapid growth of obesity and diabetes treatments has significantly increased demand for large-scale peptide synthesis, purification, and API production services, encouraging pharmaceutical companies to partner with specialized CDMOs
Borrowing their credibility for the blends is a category error
So, your skin colour could be improved
doi: 10.1152/ajpheart.01288.2004, 33
IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art